Waters Corporation (WAT) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance with better-than-expected revenue and operating margins. The Q&A section reveals optimism in growth areas like microbiology and LC-MS, and strategic localization efforts in China. Despite some uncertainties in management's responses, the overall sentiment is positive, with revenue synergies and disciplined cost management. The guidance reflects cautious optimism, and the company's strategic initiatives suggest potential for continued growth, leading to a positive outlook for the stock price.
Key Financial Performance
Total Company Revenue $1.267 billion, comprising $747 million of organic revenue and $520 million from Biosciences and Diagnostic Solutions. Organic revenue grew 13% as reported and 11% in constant currency. Biosciences and Diagnostic Solutions revenue grew an estimated 7% on a reported basis. Reasons for growth include strong execution initiatives, cross-divisional collaboration, and revenue synergies.
Adjusted Earnings Per Share (EPS) $2.70, representing a 20% year-over-year growth. Reasons for growth include strong top-line performance, disciplined cost management, and operational excellence.
Analytical Sciences Division Revenue $607 million, up 14% as reported and 12% in constant currency. Instruments grew 8%, chemistry grew 13%, and service grew 14%. Growth drivers include strong instrument replacement, adoption of new products, and cross-selling through Biosciences channel.
Advanced Diagnostics Division Revenue $349 million, with Diagnostic Solutions contributing $288 million (8% estimated growth) and Clinical Business Unit contributing $61 million (14% constant currency growth). Growth drivers include improved commercial momentum, microbiology growth, and execution initiatives.
Biosciences Division Revenue $232 million, representing 7% estimated as-reported growth. Reagents grew low double digits, while instruments faced pressure due to U.S. academic and government trends and China-related constraints. Growth drivers include improved execution and increased commercial activity.
Materials Sciences Division Revenue $79 million, up 6% as reported and 2% in constant currency. Growth drivers include strength in high-growth segments like batteries, electronics testing, and aerospace, partially offset by soft trends in core industrial applications.
Adjusted Gross Margin 54.7%, approximately 200 basis points better than expected. Reasons include effective supply chain management and mitigation of elevated costs.
Adjusted Operating Margin 23.6%, approximately 200 basis points better than expected. Reasons include strong margin results and disciplined cost management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Microflow LC Chemistry Columns with MaxPeak Premier technology: Launched in Q1 2026, these columns deliver up to twice the sensitivity of traditional microflow columns for high-throughput bioseparations, DMPK, and omics applications.
omniDAWN multi-angle light scattering detector: Recently launched, this detector is an industry-first extended range detector for UPLC, meeting rising throughput and resolution requirements.
BACTEC FXI blood culture system: Received CE marking under the EU's in vitro diagnostic regulation. It offers 60 sample loading and a 3-hour faster detection time than the previous generation.
BD Onclarity HPV self-collection kit and assay: FDA-cleared for at-home cervical cancer screening with extended genotyping for multiple high-risk strains, addressing barriers to screening access.
China market localization: Actions initiated to localize manufacturing of flow instruments in China to improve market access and reduce export complexity. Manufacturing to begin in Q3 2026.
E-commerce platform expansion: Scaled digital capabilities team to over 100 employees in Bangalore to strengthen competitive position and drive increased customer adoption of digital ordering channels.
180-day growth revitalization plan: Focused on rapid execution initiatives, including increased commercial activity, pricing discipline, and regaining share in flow research.
Cost synergies: On track to deliver $55 million in 2026 through organizational optimization, procurement savings, and network optimization.
Service plan attachment: Completed full coverage analysis of installed bases, expected to drive $20 million incremental revenue over the next 5 years.
Revenue synergies: Ahead of plan with $50 million expected in 2026, driven by cross-selling, instrument replacement, service plan attachment, and e-commerce.
Mid-term growth strategy: Three-phase plan to progressively increase growth rate from mid-single digits to high single digits, supported by operational improvements, synergy realization, and new product launches.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
China-related constraints: Ongoing export restrictions of high parameter products and lack of a localized product portfolio in China are impacting instrument sales and market access.
Respiratory testing headwinds: A weak flu season caused a $20 million revenue headwind in respiratory testing, impacting growth in the Advanced Diagnostics Division.
DRG weakness in China: Declines in Diagnostic Related Group (DRG) spending in China are negatively affecting the Clinical Business Unit and microbiology revenue.
Supply chain and cost pressures: Elevated freight costs, tariff costs, and inflationary pressures are impacting operational costs, though mitigated to some extent.
Compliance issues in U.S. Diagnostic Solutions contracts: Approximately 700 contracts are out of compliance, representing a double-digit million dollar annual revenue shortfall.
Flow research market share loss in China: Lack of localized manufacturing in China has led to share loss in flow research instruments.
Soft trends in core industrial applications: Weakness in chemicals and materials sectors is partially offsetting growth in high-growth segments like batteries and electronics testing.
Middle East conflict impact: Ongoing conflict in the Middle East is anticipated to elevate freight, raw materials, and component costs for the remainder of the year.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year 2026 Organic Constant Currency Revenue Growth: Raised to 6.5% to 8%, reflecting strong first quarter performance and embedding $15 million of expected revenue synergy contribution.
Acquired Businesses Revenue: Biosciences and Diagnostic Solutions businesses expected to generate approximately $3.035 billion of revenue in 2026, including $35 million of expected revenue synergies.
Total Reported 2026 Revenue: Expected to be approximately $6.405 billion to $6.455 billion based on latest FX rates.
Adjusted Earnings Per Share (EPS) for 2026: Raised to $14.40 to $14.60, reflecting growth of 10% to 11%.
Second Quarter 2026 Organic Constant Currency Revenue Growth: Expected to be 6% to 8%, with foreign exchange representing a headwind of approximately 0.5%.
Second Quarter 2026 Total Reported Revenue: Expected to be $1.616 billion to $1.631 billion.
Second Quarter 2026 Adjusted EPS: Expected to be in the range of $2.95 to $3.05, reflecting flat to 3.4% growth.
Adjusted EBIT Margin for 2026: Expected to be 28.2%, supported by restructuring actions and operational initiatives.
Revenue Synergies for 2026: Expected to deliver $50 million, driven by cross-selling, instrument replacement, service plan attachment, and e-commerce.
Cost Synergies for 2026: Firmly on track to deliver $55 million, driven by organizational optimization, procurement savings, and network optimization.
China Portfolio Localization: Manufacturing of flow instruments in China for China to begin in the third quarter of 2026, expected to improve market access and reduce export complexity.
New Product Launches: BACTEC FXI blood culture system launched in Europe and Japan, with additional regulatory approvals expected in other key global markets in the coming months.
At-Home Cervical Cancer Screening: FDA clearance received for BD Onclarity HPV self-collection kit and assay, with contracts signed with strategic partners for market introduction.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you elaborate on the $35 million in revenue synergies and the factors contributing to it?
A:The $35 million in revenue synergies are primarily driven by instrument replacement, service plan attachment, and e-commerce. Pricing actions, tariff neutralization, and disciplined reagent rental contracts are not included in the guide. Additionally, the 180-day plan has improved funnel reviews and field activity, with weekly call rates doubling in some areas. Localization efforts in China are also contributing to growth.
Q:What is your confidence in turning around the microbiology business, and what are the growth drivers?
A:The microbiology business has significant unmet needs and is showing 5%-6% growth despite DRG headwinds. The FXI launch is expected to augment revenue synergies and the underlying business. The team is optimistic about the business's growth potential, especially in high-volume regulated applications.
Q:Can you provide more details on the performance of the legacy Waters instrumentation side, particularly LC-MS and pharma?
A:LC-MS grew in high single digits, driven by replacement cycles, new products like Alliance iS and Xevo MRT, and growth drivers such as GLP-1 testing and biologics. Pharma saw mid-teens growth overall, with over 50% growth in China due to biotech and CDMOs, and strong performance in India generics.
Q:What are your observations on the BD business's Q1 performance and expectations for the future?
A:The BD business showed a $40 million beat, attributed to strong execution and the 180-day growth revitalization plan. The guidance has been derisked for the second half of the year, with conservative assumptions for point-of-care performance. The integration of BD and Waters teams has improved forecast accuracy and collaboration.
Q:What is the impact of extra working days on the legacy Waters business, and how does it affect guidance?
A:The extra working days contributed about 4% more recurring revenue, translating to 2% more total revenue for the legacy Waters business. The second half guidance has been adjusted to account for fewer working days and macroeconomic factors, with a cautious 6% constant currency growth assumption.
Q:How is the company addressing competition and pricing in the microbiology and flow cytometry markets?
A:The company focuses on high-volume regulated settings with leading brands. Pricing initiatives are being implemented, and the company expects rational pricing behavior from competitors, including private equity-owned businesses. Localization efforts in China for flow cytometry are underway to enhance competitiveness.
Q:What is driving the mid-teens growth in chemistry, and what is the updated guidance for the full year?
A:The growth is driven by a steady stream of new products in bioseparations, with virtually all new molecular entities starting with Waters' offerings. The full-year guidance for chemistry is set at 6.5%, reflecting a cautious approach due to a strong baseline.
Q:What is the rationale behind localizing manufacturing in China for flow cytometry, and what are the expected benefits?
A:Localization in China aims to cater to the growing pharma market, which saw over 50% growth in China. The company is leveraging its Suzhou site for this initiative, with orders expected to flow in by Q3. This strategy follows the successful localization of the Analytical Sciences business.
Q:Can you provide insights into pricing versus volume growth in the BD business and its sustainability?
A:The legacy Waters business achieved over 200 basis points of price growth, while the BD business saw 0.5%. Pricing initiatives are being implemented, but they are not yet embedded in the guide. The company sees significant opportunities in pricing, tariff mitigation, and reagent rental contract compliance.
Q:What is the status of the LC-MS instrument replacement cycle, and how does it impact future growth?
A:The replacement cycle is progressing well, with contributions from large pharma and CDMOs. Some segments, like CROs and Chinese branded generics, are yet to replace overaged fleets, providing a runway into 2027. Reshoring dynamics are expected to bridge potential gaps in 2028, ensuring seamless growth.
Q:Review of Unclear Management Responses
A:Management avoided providing specific metrics or detailed breakdowns for certain areas, such as the exact volume growth in the BD business and the precise financial impact of pricing initiatives. Additionally, while they mentioned significant opportunities in pricing and reagent rental contracts, these were not quantified or included in the guidance.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advanced Diagnostics
Analytical Sciences
BD Onclarity
Biosciences Diagnostic
Clinical Unit
DRG
Diagnostic Solutions
Diagnostics Division
FX
Onclarity HPV
Phase
Sciences Division
activity
basis Biosciences
business
cancer
channel
closing date
cost synergy
date end
day plan
flow research
forma basis
home
level cost
microbiology
period ownership
priority
screening
speed
transaction
WAT Transcript
Waters Corporation (WAT) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call summary indicates strong financial performance with better-than-expected revenue and operating margins. The Q&A section reveals optimism in growth areas like microbiology and LC-MS, and strategic localization efforts in China. Despite some uncertainties in management's responses, the overall sentiment is positive, with revenue synergies and disciplined cost management. The guidance reflects cautious optimism, and the company's strategic initiatives suggest potential for continued growth, leading to a positive outlook for the stock price.
Waters Corporation (WAT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-2
Waters Corporation (WAT) Q4 2025 Earnings Call Transcript
Positive2-9
The earnings call indicates strong financial performance with 11% EPS growth and optimistic future guidance. The transition to subscription models and new product launches are expected to drive growth. Despite some challenges in BD assets, management is confident in achieving synergies and improving execution. The Q&A section reveals cautious optimism, with a focus on pricing discipline and operational improvements. Overall, the positive guidance, strong EPS growth, and strategic initiatives suggest a positive stock price movement over the next two weeks.
Waters Corporation (WAT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
WAT Slides
WAT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
